You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
香雪製藥(300147.SZ)擬15億元購買協和精準100%股權
格隆匯 03-26 21:07

格隆匯 3 月 26日丨香雪製藥(300147.SZ)公佈,公司於2021年3月26日與控股股東廣州市崑崙投資有限公司(“崑崙投資”)、廣州協和精準醫療有限公司(“協和精準”)、王永輝簽署了《廣州市香雪製藥股份有限公司與廣州市崑崙投資有限公司與王永輝關於廣州協和精準醫療有限公司的股權轉讓協議》。根據協議約定,公司將向崑崙投資購買協和精準100%股權。此次股權轉讓價格以審計評估的股東全部權益價值結果為參考依據,經交易雙方協商確定為15億元。此次交易完成後,崑崙投資不再持有協和精準醫療的股權。

此次交易完成後,公司將在原有業務以及在生物島資產的建成基礎上,依託生物島的天然地理優勢、政策優勢、產業優勢,結合公司自身在醫藥行業的沉澱、在生物製藥行業的提前佈局,打造一個以生命科學產業為基礎,結合精準醫療、全面生命全週期健康管理、人工輔助生殖、國家組織工程庫以及智慧中醫等行業緊密銜接的新的醫學轉化平台以及生態圈。公司與協和精準之生物島項目能夠共享行業資源、技術以及管理經驗。

此次交易有利於雙方實現技術、產品、市場等方面的優勢互補,發揮公司與協和精準之生物島項目的協同效應。在行業橫向形成優勢互補,促進業務深入融合。此次交易完成後,公司在生命科學業態上的佈局以及資源更加豐富,影響力進一步擴大。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account